Invitrogen acquires CellzDirect

Wednesday, 16 January, 2008

Invitrogen, a provider of life science technologies for research, production and diagnostics, has announced a definitive agreement to purchase privately held American company CellzDirect for around $57 million.

CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs. Primary human hepatocytes are the most accepted model for predicting a compound’s effects on enzymatic metabolism in the liver. Their products are mainly used by pharmaceutical and biotech companies in research and development.

“CellzDirect’s high-value products and services will greatly complement Invitrogen’s market-leading portfolio of complete cell systems, including primary cells, media, matrices and growth factors,” said Greg Lucier, Invitrogen’s chairman and CEO.

“The purchase of CellzDirect follows our strategy of investing in high growth areas of the market, specifically specialty cell systems.”

Related News

Australian Healthcare Week 2024: register for your free pass

With more than 150 leading health sector speakers, over 100 sessions and two deep-dive master...

Recommendations released: Pathway to Diversity in STEM Review

The Pathway to Diversity in STEM Review addresses the urgent need for Australia to boost its STEM...

Built for the future: KAESER Australia unveils new facility in Vic

The 4500 m2, $15 million facility features various innovations that echo KAESER's...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd